DDInter1280 DDInter899
Nepafenac is a monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. It has a role as a prodrug, a cyclooxygenase 2 inhibitor, a cyclooxygenase 1 inhibitor, a non-steroidal anti-inflammatory drug and a non-narcotic analgesic.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Nepafenac {u} (Compound) resembles {v} (Compound) Phenacemide
Nepafenac {u} (Compound) resembles {v} (Compound) Oxcarbazepine
Nepafenac {u} (Compound) binds {v} (Gene) PTGS2
Nepafenac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nepafenac {u} (Compound) causes {v} (Side Effect) Eye discharge
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Nepafenac (Compound) resembles Phenacemide (Compound)
Nepafenac (Compound) resembles Oxcarbazepine (Compound)
Nepafenac (Compound) binds PTGS2 (Gene)
Nepafenac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Nepafenac (Compound) causes Eye discharge (Side Effect)
Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib